Key points are not available for this paper at this time.
Tumor microenvironment (TME) heterogeneity leads to a discrepancy in survival prognosis and clinical treatment response for patients with HCC. The clinical applications of documented molecular subtypes are constrained by several issues.
Chen et al. (Wed,) studied this question.